Long-Term Safety Results from a Phase 3 Open-Label Study of a Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion in Moderate-to-Severe Plaque Psoriasis

Authors

Mark G. Lebwohl
Jeffrey L. Sugarman
Linda F. Stein Gold, Henry Ford HealthFollow
David M. Pariser
Tina Lin
Radhakrishnan Pillai
Gina Martin
Susan Harris
Robert Israel

Recommended Citation

Lebwohl MG, Sugarman JL, Stein Gold LF, Pariser DM, Lin T, Pillai R, Martin G, Harris S, Israel R. Long-Term Safety Results from a Phase 3 Open-Label Study of a Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion in Moderate-to-Severe Plaque Psoriasis. J Am Acad Dermatol 2019; 80(1):282-285.

Document Type

Article

Publication Date

1-1-2019

Publication Title

J Am Acad Dermatol

PubMed ID

30227193

Volume

80

Issue

1

First Page

282

Last Page

285